Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

US9803224B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9803224-B2
Application numberUS-201715605061-A
CountryUS
Kind codeB2
Filing dateMay 25, 2017
Priority dateMay 11, 2012
Publication dateOct 31, 2017
Grant dateOct 31, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

First claim

Opening claim text (preview).

What is claimed is: 1. An engineered polypeptide having imine reductase activity, wherein said polypeptide has at least 90% sequence identity to SEQ ID NO:2, and comprises a substitution at a position corresponding to position 280 of SEQ ID NO:2, wherein the amino acid at position 280 has been replaced with an aliphatic or non-polar residue. 2. The engineered polypeptide having imine reductase activity of claim 1 , wherein said polypeptide has at least 90% sequence identity to SEQ ID NO:2, wherein the amino acid at the position corresponding to position 280 of SEQ ID NO:2 has been replaced with leucine. 3. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1a) pyruvate, and substrate compound (2b) butylamine to product compound (3b), N-2-(butylamino)propanoic acid, under suitable reaction conditions. 4. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2a) L-norvaline to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid, under suitable reaction conditions. 5. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2b) butylamine to product compound (3d), N-butylcyclohexanamine, under suitable reaction conditions. 6. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1i), and substrate compound (2b) to product compound (3n), under suitable reaction conditions. 7. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1j), and substrate compound (2b) to product compound (3o), under suitable reaction conditions. 8. A process for preparing an amine compound of formula (III), wherein (a) R 1 and R 2 groups are independently selected from the group consisting of a hydrogen atom, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted alkoxy, an optionally substituted carboxy, an optionally substituted aminocarbonyl, an optionally substituted heteroalkyl, an optionally substituted heteroalkenyl, an optionally substituted heteroalkynyl, an optionally substituted carboxyalkyl, an optionally substituted aminoalkyl, an optionally substituted haloalkyl, an optionally substituted alkylthioalkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted arylalkyl, an optionally substituted heterocycloalkyl, an optionally substituted heteroaryl, and an optionally substituted heteroarylalkyl; (b) R 1 and R 2 are linked to form a 3-membered to 10-membered ring; (c) R 3 and R 4 groups are independently selected from a hydrogen atom, and optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted alkoxy, an optionally substituted carboxy, an optionally substituted aminocarbonyl an optionally substituted heteroalkyl, an optionally substituted heteroalkenyl, an optionally substituted heteroalkynyl, an optionally substituted carboxyalkyl, an optionally substituted aminoalkyl, an optionally substituted haloalkyl, an optionally substituted alkylthioalkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted arylalkyl, an optionally substituted heterocycloalkyl, an optionally substituted heteroaryl, and an optionally substituted heteroarylalkyl, with the proviso that both R 3 and R 4 cannot be hydrogen; (d) R 3 and R 4 are linked to form a 3-membered to 10-membered ring; (e) wherein optionally, the carbon atom and/or the nitrogen indicated by * is chiral; and (f) at least one of R 1 and R 2 is linked to at least one of R 3 and R 4 ; the process comprising contacting a compound of formula (I), wherein R 1 , and R 2 are as defined above; and a compound of formula (II), wherein R 3 , and R 4 are as defined above; with an engineered polypeptide having imine reductase activity in presence of a cofactor under suitable reaction conditions, wherein the engineered polypeptide is the engineered polypeptide of claim 1 . 9. The process of claim 8 , in which R 3 and R 4 are linked to form a 3-membered to 10-membered ring. 10. The process of claim 8 , in which the substrate compound of formula (II) is selected from methylamine, dimethylamine, isopropylamine, butylamine, isobutylaminel, L-norvaline, aniline, (S)-2-aminopent-4-enoic acid, pyrrolidine, and hydroxypyrrolidine. 11. The process of claim 8 , in which at least one of R 1 and R 2 of the compound of formula (I) is linked to at least one of R 3 and R 4 of the amine compound of formula (II), whereby the process for preparing the amine compound of formula (III) comprises an intramolecular reaction. 12. The process of claim 8 , in which the suitable reaction conditions comprise: (a) substrate loading at about 10 g/L to 100 g/L; (b) about 0.1 g/L to about 50 g/L of the engineered polypeptide; (c) about 0.05 g/L (0.001 M) to about 2.5 g/L (0.050 M) of NAD(P)H; (d) a pH of about 6 to 10; (e) temperature of about 20° to 50° C.; and (f) reaction time of 2-120 hrs.

Assignees

Inventors

Classifications

  • Nitrogen as only ring hetero atom · CPC title

  • Tauropine dehydrogenase (1.5.1.23) · CPC title

  • C12N9/0028Primary

    with NAD or NADP as acceptor (1.5.1) · CPC title

  • Amines; Imines · CPC title

  • containing a six-membered hetero ring · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9803224B2 cover?
The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Who is the assignee on this patent?
Codexis Inc
What technology area does this patent fall under?
Primary CPC classification C12N9/0028. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).